- Home
- SST vs IGC Comparison
SST vs IGC Comparison
Compare SST & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- IGC
- Stock Information
- Founded
- SST 2013
- IGC 2005
- Country
- SST United States
- IGC United States
- Employees
- SST N/A
- IGC N/A
- Industry
- SST Diversified Commercial Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- IGC Health Care
- Exchange
- SST Nasdaq
- IGC Nasdaq
- Market Cap
- SST 23.3M
- IGC 20.2M
- IPO Year
- SST N/A
- IGC N/A
- Fundamental
- Price
- SST $0.36
- IGC $0.30
- Analyst Decision
- SST Strong Buy
- IGC Strong Buy
- Analyst Count
- SST 1
- IGC 2
- Target Price
- SST $5.00
- IGC $3.88
- AVG Volume (30 Days)
- SST 111.2K
- IGC 199.0K
- Earning Date
- SST 05-06-2025
- IGC 06-23-2025
- Dividend Yield
- SST N/A
- IGC N/A
- EPS Growth
- SST N/A
- IGC N/A
- EPS
- SST N/A
- IGC N/A
- Revenue
- SST $333,521,000.00
- IGC $1,236,000.00
- Revenue This Year
- SST N/A
- IGC N/A
- Revenue Next Year
- SST $6.71
- IGC $16.45
- P/E Ratio
- SST N/A
- IGC N/A
- Revenue Growth
- SST N/A
- IGC 1.65
- 52 Week Low
- SST $0.29
- IGC $0.25
- 52 Week High
- SST $1.63
- IGC $0.55
- Technical
- Relative Strength Index (RSI)
- SST 43.87
- IGC 43.81
- Support Level
- SST $0.35
- IGC $0.28
- Resistance Level
- SST $0.43
- IGC $0.32
- Average True Range (ATR)
- SST 0.04
- IGC 0.02
- MACD
- SST -0.01
- IGC -0.00
- Stochastic Oscillator
- SST 14.38
- IGC 13.33
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.